{
    "Trade/Device Name(s)": [
        "ARCHITECT Toxo IgG",
        "ARCHITECT Toxo IgG Reagent Kit",
        "ARCHITECT Toxo IgG Calibrator",
        "ARCHITECT Toxo IgG Controls"
    ],
    "Submitter Information": "Abbott Laboratories",
    "510(k) Number": "K210596",
    "Predicate Device Reference 510(k) Number(s)": [
        "K993319"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LGD"
    ],
    "Summary Letter Date": "February 26, 2021",
    "Summary Letter Received Date": "March 1, 2021",
    "Submission Date": "May 18, 2022",
    "Regulation Number(s)": [
        "21 CFR 866.3780"
    ],
    "Regulation Name(s)": [
        "Toxoplasma gondii serological reagents"
    ],
    "Analyte Class(es)": [
        "serology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Toxoplasma gondii"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT i System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent microparticle immunoassay (CMIA)"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Reagent Kit"
    ],
    "Document Summary": "FDA 510(k) summary for ARCHITECT Toxo IgG CMIA for quantitative determination of anti-Toxoplasma gondii IgG in human serum and plasma",
    "Indications for Use Summary": "Aids in detection of immune status to Toxoplasma gondii, including women of child-bearing age, and in diagnosis of Toxoplasma gondii infection using human serum and plasma; not for donor screening.",
    "fda_folder": "Microbiology"
}